Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lexeo Therapeutics's share price for the quarter that ended in Mar. 2024 was $15.68. Lexeo Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 32.93 Mil. Therefore, Lexeo Therapeutics's market cap for the quarter that ended in Mar. 2024 was $516.31 Mil.
Lexeo Therapeutics's quarterly market cap
increased
from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($357.59 Mil) and
increased
from Dec. 2023 ($357.59 Mil) to Mar. 2024 ($516.31 Mil).
Lexeo Therapeutics's annual market cap
stayed the same
from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then
increased
from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($357.59 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lexeo Therapeutics's Enterprise Value for Today is $365.38 Mil.
Lexeo Therapeutics Market Cap Historical Data
The historical data trend for Lexeo Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexeo Therapeutics's Market Cap
For the Biotechnology subindustry, Lexeo Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexeo Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's Market Cap falls into.
Lexeo Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lexeo Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics (NAS:LXEO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lexeo Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Lexeo Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexeo Therapeutics (Lexeo Therapeutics) Business Description
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LXEO has been successfully added to your 